3-D Matrix, a leading medical device company, built around self-assembling peptide (SAP) hydrogel technology pioneered by Dr. Shuguang Zhang at MIT. Headquartered in Tokyo and listed on NASDAQ, it operates globally with R&D hubs in Japan, the USA, and Europe. Its flagship product, Purastat™, is a CE-marked, FDA-cleared, and PMDA-approved class III medical device for hemostasis. The company focuses on surgery, tissue regeneration, and drug delivery, leveraging SAP's nanostructure to release various molecules including peptides, proteins, antibodies, and small-molecule drugs. Peptides within beta-sheet fibres enable diverse molecule accommodation, with tunable release profiles influenced by peptide type and concentration. SAP's biocompatibility allows versatile administration routes—topical, subcutaneous, intra-muscular, and oral. With extensive clinical data and proven biocompatibility, 3-D Matrix's peptide technology presents customizable solutions for advancing healthcare across multiple domains.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. We have developed and manufactures more than 65 products sold by customers worldwide.

We have the expertise and proven track record to guide projects from clinical research stages through optimization, validation, and approval. We operate seven facilities in the US and Europe, equipped to facilitate efficient drug product development and manufacturing, maintaining excellent environmental conditions compliant with US and EU cGMP regulations.

Adare has dedicated high potency GMP manufacturing and development areas. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care.

Aprecia is the biopharmaceutical leader in advanced additive manufacturing technologies. As a specialty CDMO,
we help you overcome formulation challenges. Through novel oral dosage forms, we are reimagining medicine so patients and caregivers can live their best lives.

We are Ardena, a reputable contract partner delivering drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with you to compile your regulatory dossier and to fast track your product towards compliance. Every day, we guide companies through the hurdles and challenges of drug development. Our integrated service offering helps to streamline the drug's progress to clinic and beyond. Ardena is your one source contractor for the chemical and pharmaceutical development of your valued compounds. In parallel, we provide you with full product analytical and bioanalytical support during development. Our dossier-centric approach makes a difference. We work with you to compile your regulatory dossier in parallel with drug development, saving you time, identifying hurdles and fast-tracking your product to compliance. We are experts in writing and formatting supporting CMC documentation.

Asahi Kasei is a highly diversified Japanese supplier of high-performance materials for various industries, including automotive, energy, electronics, housing and health care. In the fields of pharma- and nutraceuticals, we offer functional excipients. For many decades Asahi Kasei stands for quality, reliability and performance and is dedicated to “Creating for Tomorrow”.

Our key product is Ceolus, functional grades of microcrystalline cellulose (MCC) with outstanding compactability and flowability due to a special particle structure. This allows for avoiding typical formulation challenges like tablet mass segregation, capping, slow/fast disintegration, low tablet hardness or the changing of the API structure. Celphere, Asahi Kasei’s MCC spherical cores allow the combination of incompatible APIs in one tablet, achieve different release profiles and improve the acceptability of products. Special grades of our pregelatinized starch PC-10 can be applied for the protection of moisture sensitive APIs in the formulation.

Our functional excipients prove to be solutions to our customer’s daily challenges.

Ashland works alongside formulators to advance drug-specific delivery platforms with an industry-leading portfolio of pharmaceutical excipients and technical expertise including superior polymer technology and systems for optimum bioavailability.

For over 50 years, Ashland has created value for customers through applications knowledge, technical support, and a powerful product portfolio. The company offers real-time solutions based on superior binder, film coating, solubilizer, disintegrant, rheology control, cyclodextrins and modified-release technologies.

A team of technical experts at global R&D centers provide formulation development support for conventional and potent compounds as well as controlled substances to offer tailored solutions that address solubility challenges.

During this event, Ashland will showcase polymer solutions for extended release injectable depot strategies including ViatelTM bioresorbable polymers. This portfolio includes 72 GMP grades of lactide, glycolide and caprolactone copolymers as well as a customized polymer platform which supports formulators to solve complex processing, stability and delivery challenges.

Focusing On Your Formulation Needs
BASF produces excipients and active ingredients of outstanding quality and performance. With our unique expertise in polymer chemistry, our research & development capabilities and our clear commitment to developing excipients, BASF has continuously created solutions that contribute to your success and to more efficient pharmaceuticals. We deliver value added functional solutions to your formulation challenges by leveraging our expertise in delivery systems and related technologies. Our team of experienced industry specialists support you in developing effective, reliable formulations – giving you a vital advantage in a highly competitive market.

Our Platforms – Your Access To BASFs Solution Offer
BASF has been committed to the pharmaceutical industry since we introduced our original Kollidon® in the early 20th century. Since then we have continuously expanded our solution offer. Today we solve unmet formulation needs and offer intelligent solutions for today and tomorrow's challenges in drug formulation. Our four dedicated solution platforms based on current pharmaceutical market needs help you to find what you are looking for – faster than ever before. We can help with formulation challenges related to Instant and Modified Release, Solubilization, Skin Delivery, Softgels and Biologic Solutions

For more than 20 years BDD have developed and grown a world leading platform of expertise in biopharmaceutics and oral drug formulation development. Through the undertaking of clinical trials in which we have visualised the performance of products, we are able to identify and anticipate drug delivery challenges and apply this knowledge to our formulation development from an early stage. This ensures our clients take a reliable path to commercial success.

BDD helps our clients through providing crucial data for decisions through our clinical unit offering gamma scintigraphy studies and adaptive clinical trials. Our patented controlled drug release platform, OralogiK™ allows for customizable tablets for specific drug release designed with the end patient group in mind to enhance quality of life and compliance.

Our client base covers the globe, including USA, Canada, Europe, Japan, India, and Australia. Supporting businesses from virtual labs to small, medium and key global players.

Cambridge Consultants develops breakthrough products, services and intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies.

The team of more than 800 engineers, scientists, mathematicians and designers has an unparalleled track record in creating medical technology solutions that disrupt markets and revolutionize healthcare. These range from parenteral delivery devices such as pens, autoinjectors, patch pumps and large volume injectors through to medical implants and surgical drug delivery systems. The team has also pioneered high functionality, user-centred electromechanical devices combining drug delivery with wireless connectivity and eHealth service solutions to enable patient engagement and adherence.

With offices in Cambridge (UK), Boston (USA), Tokyo (Japan) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications.

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen’s Kyprolis®, Baxter International’s Nexterone®, Spectrum’s EVOMELA® and Melinta Therapeutics’ Baxdela™. There are many Captisol-enabled products currently in various stages of development.

CAS connects the world’s scientific knowledge to accelerate breakthroughs that improve lives. As a specialist in knowledge management, our team of scientists and technologists build the largest collection of human curated scientific data in the world. Our specialized content, technology, and expertise help innovators across industries navigate today’s complex information landscape and build a modern data infrastructure that integrates internal and external data sources to accelerate their progress on life changing solutions. Connect with us at cas.org.

Catalent specializes in comprehensive development, analytical and bioavailability enhancement from candidate selection to fully integrated solutions, to help get customers’ drugs to clinic faster. Using a rigorous, data-driven scientific approach, API-sparing techniques and advanced formulation technologies within a global network, Catalent helps solve complex challenges to accelerate drug development.

CLADE, a pioneer in the field since its establishment in 2001. With over two decades of dedicated experience in crafting innovative spectroscopy-based solutions. We stand as a testament to unwavering commitment in the face of evolving challenges. Our guiding principle remains unchanged: the pursuit of enhancing analytical efficiency.
In the realm of life sciences, especially biopharma, the role of effective analytics cannot be overstated. It serves as the cornerstone for upholding quality standards across a spectrum of applications. Speed, precision, and reproducibility remain priorities in every domain we touch. That’s precisely why we’ve embarked on a journey of redefining analytics, seamlessly weaving together the art of chemometrics with cutting-edge spectroscopic technology.
In essence, our mission boils down to delivering outcomes of superior quality, at an accelerated pace. Amidst the intricacies of bioanalytics, we’ve taken it upon ourselves to simplify the path. We’re making bioanalytics a journey that’s as streamlined as it is profound.

Conscio group is a European and vertically integrated Contract R&D and Manufacturing organization offering complete and innovative solutions from the idea to product. Our services include PoC, formulation and process development, manufacturing and release of IMPs & registration batches , clinical trials in our own Phase I units and (bio)analytical services. We focus on hard-to-make formulations and technologies (including high potents & narcotics) for solid, semi-solid, liquid drug products, transdermal delivery systems (TDS), oral thin films (ODF) and personalized medicine via 2D/3D printing. Our customers receive solutions tailored to their exact needs. Due to the vast pharmaceutical and technological expertise of our teams, we can de-risk development projects and accelerate time-to-market. Headquartered in Munich, Conscio Group members include Gen-Plus (Germany), Quinta-Analytica (Czech Republic), LVA (Austria), EL Labs (Slovakia), HyServe (Germany) and a representative office in the USA.

Capabilities:
•Innovation & Drug Product: Pharmaceutical R&D, feasibility, PoC, formulation and process development, scale-up, material science, permeation studies on tissue and artificial systems.
•Quality Control of Pharmaceuticals: Analytical method development and validation, GMP quality control, batch release testing, stability studies per ICH, microbiology testing, HAPIs, API sourcing.
•Quality Control of Biopharmaceuticals: Bioanalytical method development and validation, GLP/GMP bioanalysis, CMC, characterization of peptides, protein, ADCs and biosimilars.
•Clinical Solutions – Clinical Trials: 2 clinical units with a capacity for 60+36 beds, BE/BA/PK studies – planning, design and execution.
•Clinical Solutions – Bioanalysis: GLP/GCP solutions for preclinical & clinical studies, small & large molecules, statistical evaluation.
•Manufacturing solutions: cGMP-certified manufacturing of IMP clinical batches and registration batches.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Crux was founded to address challenging technical briefs and deliver compelling solutions for the drug delivery and medical device sectors. Based in Bristol, United Kingdom, our technical team champion evidence-based problem solving, coupling world-class equipment, software and facilities with a scientific approach to maximise success. Be it discovering unmet user needs, developing novel products or deploying new technologies, our team are dedicated to solving our client’s biggest problems.

Curapath is a CDMO with expertise in developing novel drug delivery systems (DDS). What sets us apart is our analytical expertise in the formulation and manufacturing of Lipid nanoparticles (LNP) and Polymer nanoparticles (PNP). When you start working with Curapath, we can support your entire therapeutic journey from development to IND. Curapath supports GMP manufacturing of Drug Substance and Drug Product for clinical trial material.

We provided unmatched technical support and analytical expertise in the custom design, development, and end-to-end GMP manufacturing of polymer and lipid-based drug delivery systems to support cell therapy, gene therapy, and vaccine delivery. For over a decade, Curapath has supported drug innovators in developing stealth shielding polymers (polyaminoacids), functional polymer & lipid excipients, linkers for bioconjugation, and API polymers used for therapeutics.

Our history of success makes Curapath the right partner to drive your therapeutic development. We deliver consultative hands-on guidance from preclinical development through commercial-scale GMP manufacturing. Curapath is a knowledgeable partner you can trust to move fast, manufacture smart, and provide support through your drug development journey, accelerating your speed to the clinic. We help our partners solve even the most complex drug delivery challenges.

DFE Pharma is a global leader in the development, production and supply of high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, OSD, ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients. With more than a century of experience and around 450 people worldwide, we serve over 5,000 customers in 100+ countries. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies to improve patient’s lives, driven by our purpose: Your medicines, and our solutions. Moving to a healthier world.

digiM is a technology leader providing CRO services in microstructure analysis and in silico modeling for the development of drug products. Combining advanced microscopic analysis with computational physics, digiM's platform provides a full spectrum understanding of drug product properties and performance. digiM works closely with developers to navigate program challenges and institutionalize knowledge libraries. In addition to services, digiM provides I2S, a cloud-based image analytics and data management platform.

Disruptive Pharma is an innovative pharmaceutical company developing novel drug products by applying our patented drug formulation technology, the mesoporous magnesium carbonate (MMC). MMC formulation technology provides an optimized amorphous formulation of small molecule drugs, harnessing the advantages of MMC to enhance solubility in water media and maximize dissolution and bioavailability. At Disruptive Pharma, we're always eager to collaborate and innovate. If your pharmaceutical company is facing challenges in formulating a drug, don't hesitate to reach out to us.

What sets MMC formulations apart is its versatility across the entire drug development chain. From in vitro studies to pre-clinical, through the clinical stages and in the final pharmaceutical product, MMC formulations prove applicable at every step, ensuring consistency and reproducibility. By a clever formulation of the active pharmaceutical ingredients (APls) using MMC platform we can develop an improved amorphous version of the current drug product. Our lead product candidate, DPH001, is an improved amorphous version of Nexavar (sorafenib), offering increased bioavailability and improved safety. During 2024 we will initiate the clinical development of DPH001. Our goal is to launch DPH001 during Q4 2026 or first half of 2027. Additional product candidates are in development.

Euroapi is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a world leader in active pharmaceutical ingredients with some 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO).

Taking action for health by enabling access to essential therapies inspires our 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, Euroapi ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext. Find out more at www.euroapi.com

Eurofins CDMO is a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with Active Pharmaceutical Ingredients (APIs)/Drug Substance and Drug Product development for biologicals and small molecules. Science is our foundation and allows us to support small and major biopharmaceutical companies achieving their pre-clinical and clinical milestones on time.

We are experts in breakthrough technologies for API development, highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs…).

Our services: API/DS Development, Solid State R&D, Preformulation, Formulation Development, GMP Manufacturing, Clinical Packaging and Logistics, CMC Regulatory Support.

Our highly-qualified project management team will propose a complete drug development strategy. Frequent communication through one single point of contact, our team's flexibility, troubleshooting mindset, customized solutions will help speed up the drug development process. Operating under strict quality procedures, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

EVEON designs and develops custom devices for preparation and delivery of advanced therapeutic treatments. We work with practitioners and patients to provide solutions in order to improve patient compliance and therapeutic performance.

Based on more than 10 years of research, EVEON has developed a recognized expertise in microfluidics to solve preparation and delivery challenges. With more than 60% of the staff dedicated to R&D and industrialisation, we cover a complete range of skills in fluidics, mechanics, electronics, software and project management.

Fluid Air, founded in 1983, is a division of Spraying Systems Co., the world leader in spray nozzle technology.

Traditional production processes like freeze drying and spray drying methods have inherent limitations for producers of biotherapeutics, pharmaceuticals, bacteria, biologics, and other high-value powders. Those processes can produce too little powder, too slowly. They are costly and difficult to scale, delaying sales and profitability.

Fluid Air is here to change that, helping our customers get to market faster — with lower cost and investment.

How do we do it?

With Our most advanced production system and proudest innovation, PolarDry® patented drying technology. It is an all-in-one system to make product with high quality, high efficiency, and reliable throughput that facilitates a seamless transition from lab scale to pilot to full production scale.

Our lab capabilities and ability to test and prove processes can bring greater success, months faster and with less risk.

And our scientists, engineers, and service team act as part of your team, providing expertise, parts, service and support for your equipment at every phase of the design, development, and manufacturing process.

The result? By using us as their process development partner, customers have accomplished great outcomes they simply could not do with traditional systems.

Since 1880, Gattefossé has been developing, manufacturing and selling pharmaceutical excipients and cosmetic ingredients of natural origin for the health and beauty industries worldwide. Gattefossé offers to the pharmaceutical industry innovative lipid excipients for oral solubilization, bioavailability enhancement, sustained release, lubrication, and taste-masking. We provide skin penetration enhancers and emulsifiers for improved topical formulations. Every product is designed with utmost attention to safety, quality, and performance consistency. As part of Gattefossé offer, technical and regulatory support is provided by fully trained experts to accelerate customers’ drug development programs thanks to our 4 Technical Centers of Excellence in France, China, India and the United States.

Environmental and social issues have always been part of our culture. Today, Gattefossé relies on a purposeful CSR approach, Gatt’Up&Act, to build its innovation and development strategy.

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer psroduces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

Glatt Pharmaceutical Services GmbH & Co. KG is the CDMO division of the Glatt Group. We develop solid pharmaceutical dosage forms with a focus on multiparticulate systems, such as pellets, granules, tablets, and capsules. We offer innovative solutions to achieve drug solubility enhancement by amorphous solid dispersions. Functional coating for taste masking and controlled drug release is another key expertise at our sites Binzen, Germany and Ramsey, New Jersey.

Our service portfolio covers the full range from feasibility studies and the formulation development over the production of clinical samples up to the bulk manufacturing of pharmaceuticals. The storage, commissioning, as well as the distribution organization of clinical samples and pharmaceuticals for market supply complete our service portfolio. In this sector, we also offer additional logistic services for import, export, and cold chain management.

Grand River Aseptic Manufacturing, Inc. (“GRAM”) is a leading contract development and manufacturing organization with advanced equipment and innovative technology that delivers customized solutions to meet clients’ fill and finish needs for liquid vials, lyophilized vials, syringes, and cartridges. With biologic, small molecule, and vaccine capabilities, Grand River Aseptic Manufacturing supports pharmaceutical development, cGMP manufacturing, analytical testing, and regulatory filing.

Haselmeier, the drug delivery device business of medmix, designs, develops and manufactures advanced drug delivery systems, such as pen injection systems and autoinjectors since more than 100 years. Patient comfort and customers’ needs are always at the heart of the company’s practices. With its broad portfolio of technologies and services, Haselmeier delivers user-friendly injection systems that enable patients to self-administer their medication reliably and accurately. Haselmeier is known for its excellent and long-standing track record of providing these innovative drug delivery devices based on its proprietary IP business model. The company collaborates closely with its customers in the pharmaceutical and biopharmaceutical industries. medmix, with its precision injection molding capabilities and expertise in liquid micro-dosing, plus financial strength and global footprint, helps Haselmeier accelerate innovation in healthcare.

Hovione offers customized services and innovative solutions from drug substance to drug product, with all activities performed at the same site. Hovione provides a fully integrated service for clinical and small commercial scale complex drug product development and manufacturing as well as formulation development for highly sophisticated inhalation and other formulations both for small molecules and biologics. As the Leader in Commercial Spray Drying, Hovione can handle projects from early-phase development to commercial and accelerates your time to market. Our particle engineering technologies can address challenges in solubility enhancement, lung delivery, modified release and taste-masking applications and can handle highly potent compounds. For biopharmaceuticals Hovione is investing by partnering in specialized particle engineering technologies, namely spray drying, aseptic spray freeze drying, nanoparticles and microemulsions. We do well what is difficult, to give our customers what they cannot find elsewhere

At IFF’s Pharma Solutions division, we provide sustainable cellulosics, seaweed extracts, ultrapure biopolymers and specialized synthetic polymers. This is supported by our polymer expertise and problem-solving mindset across the entire drug development pipeline. Our experts have decades of experience in the pharmaceutical industry and provide customization and innovation support to help differentiate your product in the market.

We pioneered excipients like Avicel® and METHOCEL™ nearly 70+ years ago and we have since created a unique range of well-known excipients designed to deliver performance and cost advantages across oral dosage, oral liquids and topicals.

As IFF, we are an even stronger partner in navigating global regulatory and supply chain complexities delivering what is best for you. A commitment to quality, service and reliability isn’t to check a box, but to drive an endless pursuit of delivering the right answers exactly when you need them.

In an ever-evolving, complex world, you can rely on IFF’s Pharma Solutions team to provide answers at every turn.

IMCD is a leading distributor, formulator, and solutions provider of speciality chemicals and ingredients.

We deliver innovation for a healthier world by providing materials and excipients with a secure and traceable supply chain, as well as technical support to help our customers in their operational and technological challenges.

Whether you need a product for your upstream or downstream process, IMCD is the ideal partner to source your ingredients. Through our collaborations with leading suppliers, our portfolio meets even the most stringent purity criteria.

We offer products used at every stage of the bio-production process:
Upstream
Downstream
Formulation

This includes ingredients with multi-compendial compliance, low bioburden and low endotoxin values. Our portfolio includes solutions with API-level documentation, as well as simpler variants.

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long-acting injectables (LAI) for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Using biodegradable polymers for microspheres, gels and implants (including ISFI) we have a unique platform to control sustained drug delivery of small molecules, peptides and proteins (including mAbs) from days, weeks to months (6).

InnoGI Technologies (formerly The TIM Company) provides innovative CRO services to the Pharmaceutical Industry related to Gastrointestinal (GI) research and Oral Drug Delivery. It utilizes the most advanced and accurate gastrointestinal technology, mimicking the dynamics of a real human gut (SurroGUT™). Our SurroGUT™ platform offers the TIM systems, a technology that is able to mimic the human GI tract with a correlation range of 76% to 99.9% with human formulation rankings. This innovative solution provides enhanced predictive capabilities, aiming to improve the overall probability of success, also in preparation for clinical trials.
InnoGI Technologies, headquartered in Delft, The Netherlands, offers a range of research services addressing complex formulation issues in oral drug candidates which can lead to decreased formulation iterations, effectively de-risked clinical trials, and shortened time-to-market. InnoGI Technologies is driven by the goal of developing innovative technologies and solutions related to realistic GI tract simulations and oral drug delivery for Pharma and Food.

Based on 60 years of experience in the development and manufacturing of scientific instruments, KNAUER also offers custom engineering of equipment for the laboratory and for GMP production.

The company’s most recent development in this field – lipid nanoparticles (LNP) production systems – have enabled the large-scale manufacturing of mRNA-based vaccines to fight the Corona pandemic.

Traditionally, KNAUER is best known for its high-precision liquid chromatography systems (HPLC and FPLC) and related components. The systems are used to analyze samples for ingredients and impurities and determine their quantities, both in the laboratory and in process analysis. The systems can also purify value substances such as active pharmaceutical ingredients on a laboratory scale.

KNAUER’s valves, pumps, detectors, and other components are also used for tasks such as high-pressure dosing and various flow detection tasks in different applications. OEM manufacturing LC components for other suppliers is an important part of KNAUER’s business.

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com

Follow @Lonza on LinkedIn

Follow @LonzaGroup on Twitter

LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches (MAP) for the transdermal delivery of large molecule, biological actives and vaccines. Founded in 1984, LTS operates today from three sites: in Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA. LTS has also a representative office in Shanghai, China.

Lubrizol Life Science – Health partners with medical device, pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and consumer benefits.

As an integrated solution provider, we co-develop solutions with our customers from concept to commercialization. Along with our best-in-class medical polymers, pharmaceutical excipients, and nutraceutical actives, we offer our design & development expertise, and advanced global manufacturing capabilities to enable your development and to accelerate your innovations to market.

About Mold-Masters®
Mold-Masters® is a leading global supplier of hot runners, controllers, auxiliary injection and co-injection systems. We design, manufacture, distribute, sell and service highly engineered and customized plastic processing equipment that caters to every market. Mold-Masters is credited for patenting the first commercially viable hot runner system in 1965. Today, Mold-Masters conducts business in more than 100 countries and employs a diverse workforce that exceeds 2,150 professionals. Mold-Masters Global Headquarters is located in Georgetown, ON Canada. Mold-Masters is an operating company of Hillenbrand (NYSE: HI).

MUNIT and its affiliates JETPHARMA and MICROCHEM operates in the field of MICRONIZATION and MILLING of Active Pharmaceutical Ingredients (APIs), High-Potent-APIs, Cytotoxic- and Cytostatic- compounds, Inhalation products, Steroids, R&D compounds and Generics.

Our services:
Jet- , Pin- and Hammer milling
Cryogenic-Micronization
Co-Micronization
Post-milling conditioning
Sieving, Blending, De-Lumping
Technical trials, DoE Studies, Process-development and Validation
QbD
PSD analysis etc.

The triangular company structure with its back-up potential, its technology transfer and the resulting flexibility is one of our unique features in the market (Business continuity).

MUNIT guarantees best service, high efficiency and punctuality to customers worldwide.

MyBiotech is an innovative SME with long years of R&D&I track as CDMO offering end to end development, manufacturing services and innovative products for biotech and pharma with proprietary production and processing technologies. MyBiotech`s mission is bringing biotechnology and pharmaceutical products into the market in a fast and efficient way.

MyPharma department, pharmaceuticals division, focuses on development and GMP production of nano- and microparticles by using the most appropriate technology including continuous manufacturing technologies. MyB`s innovative particle formulations are designed to maximize the benefits of the particulate systems and services shorten the time to market by integration of developed particulate systems to existing down processing methods and manufacturing lines. MyPharma is specialised on technology transfer of particulate formulations from concept through development all the way up to GMP manufacturing. MyB is continuously developing and adapting innovative production methods for GMP manufacturing and processing of particulate systems.

NAGASE & CO., LTD. is a global integrated business enterprise specialized in chemicals and biomaterials, founded 1832 in Japan with more than 6,900 employees. The NAGASE Group began as a specialized sales agent securing exclusive contracts to sell industry-leading products globally. Over the years, our Life & Healthcare department leveraged our application knowledge and distribution network gathering expertise for pharmaceutical raw materials our global network to transform our business into a hybrid model offering superior manufacturing, processing and R&D functions as well as pharmaceutical drug manufacturing services. Forward-looking to our 200th anniversary we are creating a platform for sustainable growth.

Our group company Nagase Viita was founded as a starch syrup manufacturer in 1883 and has grown into a company with strong research and development expertise. They were the pioneer in enzyme technology to manufacture Trehalose on industrial scale commonly used during lyophilization to stabilize not only antibodies but also wide range of biological materials including proteins, nucleotides and exosomes. Nagase Viita is the only global supplier of injectable grade Trehalose manufactured from starch. High quality Oligosaccharide manufacturing is a key competence.
Their persistent efforts in sustainable practices have led to a high rating in the sustainability survey by EcoVadis, an International evaluation agency in France.

Our global network spans

• North America
• Latin and South America
• Western Europe
• Central & Eastern Europe
• Middle East & Africa
• Russia & Eurasia
• Asia & Pacific

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline to progress to clinical development. CESS® enables lower dosage and safer products to be developed with reduced side-effects and permits combination therapies, which would otherwise be prohibited by the large dosages of either drug. The award-winning technology is also ushering in a new era of ocular, pulmonary and transdermal drug delivery applications, along with enhanced delivery of drug particles across the blood-brain barrier.

Nebu~Flow is developing a new category of nebulisers to transform respiratory drug delivery. Nebu~Flow® nebuliser platform has been developed to provide a number of advantages over existing technologies. It has shown its capability to aerosolise a wide range of formulation, and biologics, while controlling the aerosol droplet size for efficient inhalation drug delivery. In particular, company is focused on delivery of RNAi formulations.

At NextPharma, we provide a full range of pharmaceutical services from early-phase to commercialisation including formulation development, clinical trials and analytical services, commercial manufacturing and packaging across a broad range of pharmaceutical dosage forms. Our 10 sites are established 'Centres of Excellence' for each specific dosage form(s), with knowledgeable and experienced teams driving a science-led decision-making process, ensuring the manufacture of high quality drug products. Our vision is to be the most trusted, reliable and innovative European CDMO by upholding the highest industry standards and exceeding customer expectations.

NISSO HPC (Hydroxypropyl Cellulose) was first sold in Japan in 1969 and is globally approved for use as a pharmaceutical and nutraceutical excipient and as a binder for granulation, direct compression, and as a solubility enhancement matrix. NISSO HPC has been fully IPEC GMP compliant since 2010.

NISSO SSF (Sodium Stearyl Fumarate) is a lubricant (pharmaceutical additive) in the production of tablets. It is primarily used in tableting and dry granulation as a means of preventing tablet failure. The presence of hydrophilic groups in the molecule improves the disintegration time of the tablets, making it suitable for use in orally disintegrating (OD) tablets. Using NISSO SSF as a lubricant can suppress the effects of over-mixing tableting powders and improving the tablets physical properties, making it suitable for the continuous pharmaceutical manufacturing that has been gaining attention in recent years.

Nippon Soda/NISSO provides Japanese high-quality and highly functional excipients.

Nolato provide the medical and pharmaceutical industries with concept development, product design and process optimization, high-volume production, and post-processing of complex product systems and components based on advanced polymer technology and automation. We partner and work closely with companies, and involvement at an early stage allows us to help develop sustainable, successful and cost-effective products. Nolato also offer standard primary plastic packaging, breathing bags and laboratory products.

Syngene International Limited is a leading Contract Research & Development/Manufacturing Organization (CRO/CDMO) with 450+ active clients and 400+ patent credits. We have 30+ years of rich experience working with global clients across the Drug Discovery and Development continuum.

What sets us apart, is our full-service, integrated capabilities all under one roof that lower the cost of innovation and enable faster approval and commercialization of your drug development product.

Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, we help you – our customers in the global pharmaceutical and food industries – to improve people's lives. For that we look back on more than 160 years of experience. In the pharma sector, our intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of your liquid and solid pharmaceuticals. In the food industry, our flexible and reliable technologies produce and package confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for your smooth production processes. In everything we do, our more than 30 sites in almost 20 countries keep a firm eye on our impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions.

WuXi STA, a subsidiary of WuXi AppTec, is a leading CRDMO providing integrated CMC services including both API and drug product for small molecule, oligonucleotide, peptide and complex conjugate from discovery to development and commercial manufacturing.

WuXi STA has 14 R&D and manufacturing sites across Asia, North America and Europe. Our comprehensive drug product platform has a strong R&D team of 1,500+ scientists with capabilities in broad oral and parenteral dosage forms. Our bioavailability enhancement technology platform includes spray-dried dispersion, hot melt extrusion, nano suspension, softgel & liquid filled hard capsules.

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.